COMMUNIQUÉS West-GlobeNewswire

Chembio Determines Not to Proceed with Proposed Public Offering of Common Stock

25/10/2018 - 14:00

MEDFORD, N.Y., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Chembio Diagnostics, Inc. (Nasdaq: CEMI) today announced that it has determined not to proceed with the proposed public offering of $25 million of its common stock [...]

RedHill Biopharma to Present at the BIO-Europe 2018 Conference

25/10/2018 - 14:00

TEL-AVIV, Israel and RALEIGH, N.C., Oct. 25, 2018 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company primarily [...]

The Joint Corp. to Host Conference Call on Thursday, November 8 to Discuss Third Quarter 2018 Results

25/10/2018 - 14:00

SCOTTSDALE, Ariz., Oct. 25, 2018 (GLOBE NEWSWIRE) -- The Joint Corp. (NASDAQ: JYNT), a national operator, manager and franchisor of chiropractic clinics, announced it will report its third quarter 2018 financial results [...]

AMAG Pharmaceuticals to Host Third Quarter 2018 Financial Results Conference Call and Webcast on Thursday, November 1, 2018 at 8:00 a.m. ET

25/10/2018 - 14:00

WALTHAM, Mass., Oct. 25, 2018 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that its third quarter 2018 financial results will be released on Thursday, November 1, 2018 before the U.S. [...]

Fibrocell Receives Guidance from FDA on Phase 3 Clinical Trial Design for FCX-007

25/10/2018 - 14:00

Company Plans to Submit Phase 3 Protocol to FDA in Fourth Quarter of 2018 and Commence Trial in First Half of 2019 EXTON, Pa., Oct. 25, 2018 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ: FCSC), a gene therapy [...]

SoldierStrong Honors The Vince and Linda McMahon Family Foundation At 5th Annual SoldierSalute Gala

25/10/2018 - 14:00

Nonprofit’s 2018 Notable Corporate and Individual Supporters to Also be Honored STAMFORD, Conn., Oct. 25, 2018 (GLOBE NEWSWIRE) -- SoldierStrong, a nonprofit organization dedicated to providing advanced medical [...]

Spark Therapeutics Launches New Initiative to Raise Awareness of the Importance of Genetic Testing for People Living with Inherited Retinal Diseases

25/10/2018 - 13:30

The Eye Want 2 Know digital resource helps patients and their families in the U.S. living with an inherited retinal disease (IRD) learn about genetic testing and includes a “Find A Provider” tool to locate health care [...]

Conatus Pharmaceuticals to Report Third Quarter 2018 Financial Results

25/10/2018 - 13:30

SAN DIEGO, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the third quarter ended September 30, 2018, after the market close on [...]

Avadel Pharmaceuticals to Report Third Quarter 2018 Financial Results

25/10/2018 - 13:30

DUBLIN, Ireland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on providing innovative medicines for chronic urological, central nervous system, and sleep disorders, [...]

Moleculin Announces Positive Data on WP1066 in Pre-Clinical Trials

25/10/2018 - 13:30

HOUSTON, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company focused on the development of oncology drug candidates, all of [...]

VANC Pharmaceuticals Inc. Will Change Its Name to Avricore Health Inc. Reflecting Its New Initiatives and Focus

25/10/2018 - 13:30

VANCOUVER, B.C., Oct. 25, 2018 (GLOBE NEWSWIRE) -- VANC Pharmaceuticals Inc. ( “VANC” ) is pleased to announce that it will seek TSX Venture Exchange (the “TSXV”) approval to change the name of the Company to Avricore [...]

Integrated Cannabis Company, Inc. Enters into Licensing Agreement for Cannabidiol (CBD) Gummy Formulation

25/10/2018 - 13:30

VANCOUVER, British Columbia, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Integrated Cannabis Company, Inc. (CSE: ICAN, OTCQB: ICNAF) (“ Integrated Cannabis ”), is pleased to announce an agreement to license Cannabidiol (CBD) [...]

Ossur Hf : Interim report Q3 2018

25/10/2018 - 08:01

Announcement no. 63/2018 Interim report Q3 2018 25 October 2018 Highlights Organic sales growth of 7% in Q3 2018 and 5% in USD. Organic sales growth of 5% in 9M 2018. The prosthetics segment grew 11% organic in Q3 2018 [...]

Nexstim secures Business Finland funding for the development of wireless EMG devices

25/10/2018 - 08:01

Nexstim secures Business Finland funding for the development of wireless EMG devices The development project, to be funded by Business Finland, is part of ELASTRONICS, the largest research project in the field of [...]

Axovant Announces Dosing of First Patient in Clinical Study of AXO-Lenti-PD, a Novel Gene Therapy for Patients With Parkinson’s Disease

25/10/2018 - 08:00

Initial data from the first cohort expected in first half of 2019 BASEL, Switzerland, Oct. 25, 2018 (GLOBE NEWSWIRE) -- Axovant Sciences (NASDAQ:AXON), a company developing innovative gene therapies for neurologic and [...]

Rule 2.9 Announcement

25/10/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 25 October 2018 [...]

VALNEVA Receives Positive Feedback from EMA on its further Development for Lyme Disease Vaccine VLA15

25/10/2018 - 07:01

Valneva Receives Positive Feedback from EMA on its further Development for Lyme Disease Vaccine VLA15 Saint Herblain (France), October 25, 2018 - Valneva SE ("Valneva" or "the Company"), a commercial stage biotech [...]

VALNEVA reçoit un avis positif de l'EMA sur le plan de développement de son vaccin contre la maladie de Lyme

25/10/2018 - 07:01

Valneva reçoit un avis positif de l'EMA sur le plan de développement de son vaccin contre la maladie de Lyme Saint Herblain (France), 25 octobre 2018 - Valneva SE ("Valneva" ou "le Groupe"), société de biotechnologie [...]

Vistin Pharma ASA : 11 per cent revenue growth in third quarter 2018

25/10/2018 - 07:01

Oslo, Norway, 25 October 2018 Vistin Pharma delivered a revenue growth of 11 percent from NOK 46.7 million in the third quarter 2017 to NOK 51.7 million in the third quarter 2018. The underlying demand for metformin is [...]